Development and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM.

Zheng, Caiyun; Huang, Shunmin; Lin, Meimei; Hong, Baohui; Dai, Hengfen; Yang, Jing

Zheng, Caiyun; Huang, Shunmin; Lin, Meimei; Hong, Baohui; Dai, Hengfen; Yang, Jing.

Afiliación

Zheng C; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Huang S; Fuqing City Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China.
Lin M; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Hong B; College of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.
Dai H; Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Yang J; College of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.

J Clin Transl Hepatol ; 11(6): 1387-1396, 2023 Nov 28.

Article en En | MEDLINE | ID: mdl-37719962

Palabras clave

Checkpoint inhibitor-related immune-mediated liver injury; Hepatotoxicity; Risk factors; Sintilimab; Updated RUCAM

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Transl Hepatol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google